Indoco Remedies Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

The Indoco Remedies Q2 results FY27 announcement is the next scheduled earnings event for Indoco Remedies Ltd., Indoco Remedies Ltd. manufactures and markets generic and branded pharmaceutical formulations for domestic and international markets.. The stock traded at Rs 238.10 on the NSE on 16 September 2026, down 1.36% from the previous close of Rs 241.39, about 26.7% below its 52-week high of Rs 325.00 and 46.8% above its 52-week low of Rs 162.19.

What makes the Indoco Remedies Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 485.00 crore of revenue and a loss of Rs 9.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 468.00 crore and a profit of Rs 65.00 crore. Everything below is built from those reported figures rather than from any forecast.

Click Here – Get Free Investment Predictions

When Is the Indoco Remedies Q2 Results FY27 Date?

The Indoco Remedies Q2 results date for FY27 is not confirmed. As of 16 September 2026, Indoco Remedies Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.

What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Indoco Remedies Q2 results date becomes public through that filing rather than through any advance announcement.

Also read – Gujarat Fluorochemicals Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

The Indoco Remedies Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Indoco Remedies.

Indoco Remedies Q2 Results Expectations: What the Market Is Actually Tracking

No verified analyst estimate for the Indoco Remedies Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Indoco Remedies. The Indoco Remedies Q2 results watchlist below is built from what the company has actually reported and disclosed.

Indoco Remedies Q2 results are being watched against a five-quarter revenue path that has stayed relatively steady even as profitability struggled. Revenue was Rs 440 crore in Jun25, rose to Rs 485 crore in Sep25, eased to Rs 445 crore in Dec25, rose again to Rs 476 crore in Mar26, and stood at Rs 468 crore in Jun26. This revenue range of roughly Rs 440 crore to Rs 485 crore has held fairly narrow even while the company's bottom line moved through a difficult stretch. Those following Indoco Remedies Q2 results for the September 2026 quarter will likely focus more on the profit line than on revenue, given what happened below the operating level in recent quarters. The Indoco Remedies Q2 results series illustrates a business where the top line has been more stable than earnings.

Operating margin at Indoco Remedies improved unevenly across the five quarters: 4.0% in Jun25, 9% in Sep25, 7% in Dec25, 10% in Mar26, and 9% in Jun26. Net profit tells a starker story. Indoco Remedies reported net losses in four consecutive quarters: Rs 36 crore lost in Jun25, Rs 9 crore lost in Sep25, Rs 29 crore lost in Dec25, and Rs 24 crore lost in Mar26, before swinging to a net profit of Rs 65 crore in Jun26. That Jun26 profit figure is larger than the quarter's own operating profit of Rs 41 crore, which points to a material non-operating item, such as a one-off gain, forex movement, or tax credit, behind the swing rather than a clean operational turnaround. That distinction matters for how Indoco Remedies Q2 results are interpreted this cycle, and Indoco Remedies Q2 results should be described plainly as four straight quarters of losses followed by a profit boosted by items below the operating line, not as confirmation of a turnaround.

On valuation, standard P/E and EPS figures are not meaningful for Indoco Remedies given the trailing loss position across most of the review period, so these ratios should not be treated as a valuation signal right now. Book value is Rs 102 per share, and against the current price the stock trades at a price-to-book of about 2.3 times. Return on capital employed is near zero at 0.96% and return on equity is negative at -9.36%, both reflecting the string of losses from Jun25 through Mar26. The dividend yield is minimal at 0.08%. Debt-to-equity stands at 1.16, a moderate level. Anyone following Indoco Remedies Q2 results should treat the four consecutive quarterly net losses as real reported losses and the Jun26 profit as a swing driven partly by a non-operating item rather than a clean like-for-like recovery. Indoco Remedies Q2 results for the September 2026 quarter will need to be read carefully in that light, and Indoco Remedies Q2 results overall highlight the gap between headline profit and core operating performance.

Check Indoco Remedies Ltd. Live Fundamentals on the Univest Screener

Indoco Remedies Q2 Results Preview: The Q1 FY27 Actuals It Builds On

Indoco Remedies Ltd. reported revenue of Rs 468.00 crore in Q1 FY27, up 6.36% from Rs 440.00 crore in Q1 FY26, and a profit of Rs 65.00 crore at the net level, a swing from a loss of Rs 36.00 crore in Q1 FY26 to a profit of Rs 65.00 crore. These are reported actuals, not estimates.

Also read – Gabriel India Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

Sequentially, revenue was down 1.68% over the March 2026 quarter figure of Rs 476.00 crore, and net profit was a swing from a loss of Rs 24.00 crore in Q4 FY26 to a profit of Rs 65.00 crore. Operating margin stood at 4.0% in Q1 FY27 against 9.0% in the September 2025 quarter, which is the comparison the Indoco Remedies Q2 results print will be read against.

Q2 FY26 Base: The Comparison Indoco Remedies Q2 Results FY27 Must Beat

Indoco Remedies Ltd. reported revenue of Rs 485.00 crore and a loss of Rs 9.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Indoco Remedies Q2 results preview.

Because the base quarter itself was loss-making, a year-on-year percentage comparison of profit is not meaningful for Indoco Remedies. The more useful test in the Indoco Remedies Q2 results print is whether the company reports a profit at all, and how the income line of Rs 485.00 crore compares with the Rs 468.00 crore of the June 2026 quarter.

Indoco Remedies Quarterly Results Trend Over the Last Four Quarters

Quarter	Revenue (Rs Cr)	Net Profit (Rs Cr)
Q2 FY26 (Sep 2025)	485.00	(9.00)
Q3 FY26 (Dec 2025)	445.00	(29.00)
Q4 FY26 (Mar 2026)	476.00	(24.00)
Q1 FY27 (Jun 2026)	468.00	65.00

Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company's exchange filings, and they are the only basis this Indoco Remedies Q2 results preview uses.

Revenue across those four quarters ranged from Rs 445.00 crore to Rs 485.00 crore, and net profit from Rs 29.00 crore loss to Rs 65.00 crore. That spread is the honest context for the Indoco Remedies Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.

Key Factors That Could Shape Indoco Remedies Q2 Results FY27

The Indoco Remedies Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Indoco Remedies has already reported.

Valuation Snapshot

P/E and EPS are not meaningful for Indoco Remedies given the trailing loss position through most of the review period, so these ratios should not be read as valuation signals at present. Book value is Rs 102 per share, putting the price-to-book ratio at about 2.3 times the current price. Return on capital employed is near zero at 0.96% and return on equity is negative at -9.36%, both reflecting the string of losses reported from Jun25 through Mar26. The dividend yield is minimal at 0.08%. These figures point to a company still working through profitability challenges rather than one offering a clean valuation picture.

Technical and Price Context

Indoco Remedies shares have traded between a 52-week low of Rs 162.19 and a 52-week high of Rs 325, with the current price around Rs 238.1 positioned above the 50-day average of roughly Rs 229.32 but below the 200-day average of roughly Rs 251.03. The relative strength index reads 49.71, close to the midpoint of the typical range. This places the stock in a fairly neutral technical position relative to both its shorter and longer-term trend lines.

Balance Sheet and Payout

Indoco Remedies carries a debt-to-equity ratio of 1.16, a moderate level of borrowing on the balance sheet. The dividend yield is minimal at 0.08%, consistent with a company that reported net losses in four of the last five quarters and limited room for payouts. The Jun26 swing to a Rs 65 crore net profit, which exceeded that quarter's Rs 41 crore operating profit, points to a non-operating item behind the result and should be treated as a data point to verify rather than a confirmed turnaround.

Indoco Remedies Q2 Results FY27: Share Price and Valuation Going Into the Print

Indoco Remedies share price today is Rs 238.10 on the NSE, down Rs 3.29 or 1.36% from the previous close of Rs 241.39 on 16 September 2026, ahead of the Indoco Remedies Q2 results announcement.

Metric	Value (16 September 2026)
NSE Symbol	INDOCO
Current Market Price	Rs 238.10
52-Week High	Rs 325.00
52-Week Low	Rs 162.19
Market Capitalisation	Rs 2198 crore
PE Ratio	Not meaningful on a trailing loss
PB Ratio	2.33
EPS (TTM)	Not meaningful on a trailing loss
Book Value per Share	Rs 102.00
Debt to Equity	1.16
Return on Equity	-9.36%
50-Day Moving Average	Rs 229.32
200-Day Moving Average	Rs 251.03
RSI (14)	49.71

The stock trades above its 50-day average of Rs 229.32 but below its 200-day average of Rs 251.03, with a 14-day RSI of 49.71. None of this is a view on where the shares go once the Indoco Remedies Q2 results are announced, and no price target is offered here.

Download the Univest iOS App or Univest Android App to track Indoco Remedies Ltd. live price and quarterly earnings updates.

What Investors Should Watch When Indoco Remedies Q2 Results Are Announced

Four lines carry most of the information in a company of this size, and reading them in order keeps the Indoco Remedies Q2 results print in proportion.

1. Revenue against the Rs 485.00 crore reported in the September 2025 base quarter
2. Net profit against a loss of Rs 9.00 crore in that same quarter
3. Operating margin against 4.0% in Q1 FY27
4. Any exceptional item, provision or one-off gain disclosed alongside the numbers

A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Indoco Remedies Q2 results announcement should be read together with the notes to the results rather than the headline alone.

Conclusion on Indoco Remedies Q2 Results FY27

The Indoco Remedies Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Indoco Remedies Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.

On that basis the Indoco Remedies Q2 results FY27 print faces a base of Rs 485.00 crore in revenue and a loss of Rs 9.00 crore, with the most recent quarter having delivered Rs 468.00 crore and a profit of Rs 65.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Indoco Remedies, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.

FAQs on Indoco Remedies Q2 Results FY27

What is the Indoco Remedies Q2 results date for FY27?

Ans. The Indoco Remedies Q2 results date for FY27 is not confirmed. Indoco Remedies Ltd. had not filed a board meeting intimation with the NSE or BSE as of 16 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.

What quarter do the Indoco Remedies Q2 results 2026 cover?

Ans. The Indoco Remedies Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Indoco Remedies Ltd. reports revenue, operating profit and net profit for that period, and the Indoco Remedies Q2 results filing also carries the notes to the accounts.

What were the Indoco Remedies Q1 FY27 results?

Ans. Indoco Remedies Ltd. reported revenue of Rs 468.00 crore in Q1 FY27 and a profit of Rs 65.00 crore at the net level. Revenue was up 6.36% versus Q1 FY26 and net profit was a swing from a loss of Rs 36.00 crore in Q1 FY26 to a profit of Rs 65.00 crore.

What were Indoco Remedies Q2 FY26 results in the September 2025 quarter?

Ans. Indoco Remedies Ltd. reported revenue of Rs 485.00 crore and a loss of Rs 9.00 crore in Q2 FY26. Operating margin was 9.0%. Those figures form the base for the Indoco Remedies Q2 results FY27 comparison.

What are the main Indoco Remedies Q2 results expectations this quarter?

Ans. No verified analyst estimate is publicly available. The Indoco Remedies Q2 results expectations centre on revenue against the Rs 485.00 crore base, net profit against a loss of Rs 9.00 crore, operating margin against 4.0% in Q1 FY27, and any exceptional item disclosed with the numbers.

What is Indoco Remedies share price today ahead of the Q2 earnings?

Ans. Indoco Remedies share price is Rs 238.10 on the NSE as of 16 September 2026, down 1.36% from Rs 241.39. The stock is about 26.7% below its 52-week high of Rs 325.00 and 46.8% above its 52-week low of Rs 162.19, at a market capitalisation of Rs 2198 crore.

Is Indoco Remedies a good stock to buy before the Q2 results?

Ans. This article does not offer a buy, sell or hold recommendation on Indoco Remedies Ltd. The stock trades at a price-to-book ratio of 2.33 with a return on equity of -9.36%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.